Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up

Coronary Artery Disease

Volumn 26, Issue 1, 2016, Pages 5-10

  Zhao, Liang Ping ^a,b   Xu, Wei Ting ^b   Wang, Li ^b   Li, Hui ^b   Shao, Chun Lai ^b   Gu, Hai Bo ^b   Chan, Siew Pang ^c,d   Xu, Hai Feng ^a   Yang, Xiang Jun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c Dept Medicine Endocrinol Diabet   (Singapore)

^d LA TROBE UNIVERSITY   (Australia)

Author keywords

drug eluting stent; hyperinsulinemia; insulin resistance index; predictor; restenosis

Indexed keywords

GLUCOSE; INSULIN; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY STENTING; DISEASE ASSOCIATION; DRUG ELUTING CORONARY STENT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; IN-STENT RESTENOSIS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; ADVERSE EFFECTS; ANALYSIS; BLOOD; CHI SQUARE DISTRIBUTION; CHINA; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DEVICES; DRUG ELUTING STENT; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PROSTHESIS; RADIOGRAPHY; RISK; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; BIOMARKERS; BLOOD GLUCOSE; CHI-SQUARE DISTRIBUTION; CHINA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROSTHESIS DESIGN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84918535162     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0000000000000170     Document Type: Article

References (32)

1. Mnjoyan ZH, Doan D, Brandon JL, Felix K, Sitter CL, Rege AA, et al. The critical role of the intrinsic VSMC proliferation and death programs in injuryinduced neointimal hyperplasia. Am J Physiol Heart Circ Physiol 2008; 294: H2276-H2284.
2. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, et al. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 1996; 94:1247-1254.
3. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008; 372:1163-1173.
4. Yanase M, Takatsu F, Tagawa T, Kato T, Kovasu M, Horibe H, et al. Insulin resistance and fasting hyperinsulinemia are risk factors for new cardiovascular events in patients with prior coronary artery disease and normal glucose tolerance. Circ J 2004; 68:47-52.
5. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol 2007; 49:2112-2119.
6. Zhao LP, Lü AK, Shen WF, Liu HF, Ma XY, Fan XM, Zhang Q. Influence of insulin resistance on long-term outcomes in patients with coronary artery disease after sirolimus-eluting stent implantation. Chin Med J (Engl) 2010; 123:651-657.
7. Pfeifle B, Ditschuneit H. Effect of insulin on growth of cultured human arterial smooth muscle cells. Diabetologia 1981; 20:155-158.
8. Stout RW, Bierman EL, Ross R. Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res 1975; 36:319-327.
9. Lima-Filho MO, Figueiredo GL, Foss-Freitas MC, Foss MC, Marin-Neto JA. Predictors of restenosis after percutaneous coronary intervention using baremetal stents: a comparison between patients with and without dysglycemia. Braz J Med Biol Res 2010; 43:572-579.
10. Nishio K, Shigemitsu M, Kusuyama T, Fukui T, Kawamura K, Itoh S, et al. Insulin resistance in nondiabetic patients with acute myocardial infarction. Cardiovasc Revasc Med 2006; 7:54-60.
11. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB III, Loop FD, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1988; 78:486-502.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
13. Fishman RF, Kuntz RE, Carrozza JP Jr, Miller MJ, Senerchia CC, Schnitt SJ, et al. Long-term results of directional coronary atherectomy: predictors of restenosis. J Am Coll Cardiol 1992; 20:1101-1110.
14. Le Feuvre C, Bonan R, Lespérance J, Gosselin G, Joyal M, Crépeau J. Predictive factors of restenosis after multivessel percutaneous transluminal coronary angioplasty. Am J Cardiol 1994; 73:840-844.
15. Bakhai A, Booth J, Delahunty N, Nugara F, Clayton T, McNeill J, et al. The SV stent study: a prospective, multicentre, angiographic evaluation of the Biodiv-sio phosphorylcholine coated small vessel stent in small coronary vessels. Int J Cardiol 2005; 102:95-102.
16. Agostoni P, Valgimigli M, Biondi-Zoccai GG, Abbate A, Garcia Garcia HM, Anselmi M, et al. Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: insights from a systematic overview of randomized trials in light of the drug-eluting stent era. Am Heart J 2006; 151:682-689.
17. Colombo A, Latib A. Treatment of drug-eluting stent restenosis with another drug-eluting stent: do not fail the second time. Rev Esp Cardiol 2008; 61:1120-1122.
18. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007; 28:2706-2713.
19. Hwang IK, Kim YK, Rha SW, Ra JE, Seo BS, Lee JK, et al. Impact of insulin resistance on 1-year clinical outcomes in non-diabetic patients undergoing percutaneous coronary intervention with drug-eluting stents. J Cardiol 2013; 61:113-116.
20. Abhijit S, Bhaskaran R, Narayanasamy A, Chakroborty A, Manickam N, Dixit M, et al. Hyperinsulinemia-induced vascular smooth muscle cell (VSMC) migration and proliferation is mediated by converging mechanisms of mitochondrial dysfunction and oxidative stress. Mol Cell Biochem 2013; 373:95-105.
21. Li F, Xia K, Sheikh MS, Cheng J, Li C, Yang T. Retinol binding protein 4 promotes hyperinsulinism-induced proliferation of rat aortic smooth muscle cells. Mol Med Rep 2014; 9:1634-1640.
22. Takagi T, Yoshida K, Akasaka T, Kaji S, Kawamoto T, Honda Y, et al. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients: a serial intravascular ultrasound study. J Am Coll Cardiol 2000; 36:731-738.
23. Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Forudi F, et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 2003; 107:2238-2243.
24. Spadaccio C, Patti G, De Marco F, Coccia R, Di Domenico F, Pollari F, et al. Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study). Am J Cardiol 2013; 112:21-26.
25. Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 1996; 334:561-566.
26. Liistro F, Stankovic G, Di Mario C, Takagi T, Chieffo A, Moshiri S, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 2002; 105:1883-1886.
27. Tada T, Byrne RA, Cassese S, King L, Schulz S, Mehilli J, et al. Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease. Am Heart J 2013; 165:80-86.
28. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002; 106:2649-2651.
29. Montone RA, Sabato V, Sgueglia GA, Niccoli G. Inflammatory mechanisms of adverse reactions to drug-eluting stents. Curr Vasc Pharmacol 2013; 11:392-398.
30. Li G, Hu Y, Yang W, Jiang Y,Wang J, Xiao J, et al. DA Qing IGTand Diabetes Study. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the DA Qing IGT and Diabetes Study. Diabetes Res Clin Pract 2002; 58:193-200.
31. Fineschi M, Gori T, Pierli C, Bravi A. Late thrombosis or in-stent restenosis? Heart 2006; 92:1820.
32. Alfonso F, Fernandez-Viña F, Medina M, Hernandez R. Neoatherosclerosis: the missing link between very late stent thrombosis and very late in-stent restenosis. J Am Coll Cardiol 2013; 61:e155.